TY - JOUR KW - Canada/epidemiology KW - Cohort Studies KW - *Diabetes Mellitus, Type 2/drug therapy/epidemiology KW - *Dipeptidyl-Peptidase IV Inhibitors/therapeutic use KW - Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/therapeutic use KW - Glucagon-Like Peptide 1 KW - Glucagon-Like Peptide-1 Receptor/agonists KW - Glucose KW - Humans KW - Hypoglycemic Agents/pharmacology/therapeutic use KW - Sodium KW - *Sodium-Glucose Transporter 2 Inhibitors/therapeutic use KW - *Symporters/therapeutic use KW - United Kingdom/epidemiology KW - Type 2 diabetes KW - dipeptidyl peptidase 4 inhibitors KW - glucagon-like peptide 1 receptor agonists KW - sodium-glucose co-transporter 2 inhibitors KW - not involving SGLT-2 inhibitors or DPP-4 inhibitors. AU - V. Brunetti AU - A. St-Jean AU - S. Dell'Aniello AU - A. Fisher AU - O. H. Y. Yu AU - S. Bugden AU - J. Daigle AU - N. Hu AU - S. Alessi-Severini AU - B. Shah AU - P. Ronksley AU - L. Lix AU - P. Ernst AU - K. Filion AD - Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada. Center for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, 3755 Côte Ste Catherine, Suite H410.1, Montreal, Quebec, H3T 1E2, Canada. Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada. Division of Endocrinology, Department of Medicine, Jewish General Hospital, Quebec, Montreal, Canada. College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada. School of Pharmacy, Memorial University of Newfoundland, St John's, Newfoundland and Labrador, Canada. Institut national d'excellence en santé et en services sociaux (INESSS), Quebec, Quebec, Canada. The Health Quality Council, Saskatoon, Saskatchewan, Canada. Manitoba Centre for Health Policy, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada. ICES, Toronto, Ontario, Canada. Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. Department of Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada. Department of Medicine, McGill University, Quebec, Montreal, Canada. Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada. kristian.filion@mcgill.ca. Center for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, 3755 Côte Ste Catherine, Suite H410.1, Montreal, Quebec, H3T 1E2, Canada. kristian.filion@mcgill.ca. Department of Medicine, McGill University, Quebec, Montreal, Canada. kristian.filion@mcgill.ca. AN - 36175881 BT - BMC Endocr Disord C2 - PMC9520836 DO - 10.1186/s12902-022-01140-1 DP - NLM ET - 2022/09/30 LA - eng M1 - 1 N1 - 1472-6823 Brunetti, Vanessa C St-Jean, Audray Dell'Aniello, Sophie Fisher, Anat Yu, Oriana H Y Bugden, Shawn C Daigle, Jean-Marc Hu, Nianping Alessi-Severini, Silvia Shah, Baiju R Ronksley, Paul E Lix, Lisa M Ernst, Pierre Filion, Kristian B Canadian Network for Observational Drug Effect Studies (CNODES) Investigators Journal Article BMC Endocr Disord. 2022 Sep 29;22(1):241. doi: 10.1186/s12902-022-01140-1. PY - 2022 SN - 1472-6823 EP - 241 T2 - BMC Endocr Disord TI - Characteristics of new users of recent antidiabetic drugs in Canada and the United Kingdom VL - 22 ER -